Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Thromb Res. 2017 Oct 7;160:1–8. doi: 10.1016/j.thromres.2017.10.003

Table 3.

The association between proposed biomarkers and poor outcomes

Author/year
(ref.)		 Biomarker (s) Measurement
Method		 Relationship to
anticoagulation
(AC)		 Association between FVIII and
recurrence		 Comments
Acute phase (< one month post event)
Goldenberg 2004 (16) FVIII One-stage clotting assay On AC FVIII >150 IU per dL in 28/55 (51%) in those with poor outcome vs. 3/27 (11%) of good outcome group; p=0.061 OR of 8.9 (95% CI 2.2–36.3; P=0.002) described for FVIII and D-dimer in combination.
D-dimer Latex-agglutination assay On AC D-dimer > 500 ng per milliliter in 67% good outcome group vs. 38% good outcome group; p=0.03 FVIII and D-dimer were assessed together. Similarly, outcomes were not individually assessed, rather ‘poor outcome group’ constituted those with persistent thrombosis, recurrent VTE and PTS
Sub-acute and early chronic phase (1–6 months post event)
Goldenberg 2004 (16) FVIII One-stage clotting assay Not specified FVIII > 150 IU per deciliter in 16/32(50%) those with poor outcome vs. 17/43 (39%) in those with good outcome group; p=0.01 OR of 4.1 (95% CI 1.4–11.6; p=0.008) described for FVIII and D-dimer in combination.
D-dimer Latex-agglutination assay Not specified D-dimer > 500 ng per milliliter in 56 % good outcome group vs. 24% good outcome group; p=0.03 FVIII and D-dimer were assessed together. Similarly, outcomes were not individually assessed, rather ‘poor outcome group’ constituted those with persistent thrombosis, recurrent VTE and PTS

AC, anticoagulation